Literature DB >> 28578343

Filter Size Not the Anticoagulation Method is the Decisive Factor in Continuous Renal Replacement Therapy Circuit Survival.

Monika Miklaszewska1, Przemysław Korohoda2, Katarzyna Zachwieja1, Krzysztof Kobylarz3, Constantinos J Stefanidis4, Alina Sobczak5, Dorota Drożdż1.   

Abstract

BACKGROUND/AIM: As continuous renal replacement therapy (CRRT) has emerged as a standard therapy in pediatric intensive care units (PICU), many related issues that may have an impact on circuit survival have gained in importance. Objective of the study was an evaluation of factors associated with circuit survival, including anticoagulation (ACG).
METHODS: Retrospective study that included 40 patients, who in total received 7636 hours of CRRT during 150 sessions (84 filters, 4260 hours with heparin anticoagulation (Hep-ACG); 66 filters, 3376 hours with regional citrate anticoagulation (RCA)).
RESULTS: The Kaplan-Meier analysis of the total circuit survival time depending on the type of ACG did not demonstrate a significant difference between Hep-ACG and RCA. The percentage of clotted filters was significantly higher in case of smaller filters (HF20: 58.8%; ST60: 29.5%; ST100: 15.8%), and their lifetime was significantly lower regardless of ACG (the mean and median lifetime for HF20: 38.7/27.0 h; for ST60: 54.1/72.0 h., for ST100: 62.1/72.0 h, respectively).
CONCLUSIONS: Irrespectively of filter size, filter clotting occurs within the first 24 hours after the initiation of CRRT. Most commonly, clotting affects small filters, and their lifetime is significantly shorter as compared to larger filters regardless of the type of the ACG.
© 2017 The Author(s). Published by S. Karger AG, Basel.

Entities:  

Keywords:  Anticoagulation; CRRT; Circuit; Clotting; Filter; PICU

Mesh:

Substances:

Year:  2017        PMID: 28578343     DOI: 10.1159/000477609

Source DB:  PubMed          Journal:  Kidney Blood Press Res        ISSN: 1420-4096            Impact factor:   2.687


  4 in total

1.  Anticoagulation in patients with acute kidney injury undergoing kidney replacement therapy.

Authors:  Rupesh Raina; Ronith Chakraborty; Andrew Davenport; Patrick Brophy; Sidharth Sethi; Mignon McCulloch; Timothy Bunchman; Hui Kim Yap
Journal:  Pediatr Nephrol       Date:  2021-10-19       Impact factor: 3.651

2.  Monitoring Anticoagulation with Unfractionated Heparin on Renal Replacement Therapy. Which is the Best aPTT Sampling Site?

Authors:  Florin Ioan Anton; Paul Adrian Rus; Natalia Hagau
Journal:  J Crit Care Med (Targu Mures)       Date:  2020-08-11

Review 3.  Regional Citrate Anticoagulation and Systemic Anticoagulation during Pediatric Continuous Renal Replacement Therapy: A Systematic Literature Review.

Authors:  Emanuele Buccione; Stefano Bambi; Laura Rasero; Lorenzo Tofani; Tessa Piazzini; Carlo Della Pelle; Khadija El Aoufy; Zaccaria Ricci; Stefano Romagnoli; Gianluca Villa
Journal:  J Clin Med       Date:  2022-05-31       Impact factor: 4.964

4.  Timed Controlled Repeated Rotation of the CAR-170-C NXSTAGE Chronic Cartridge Hemodialysis Filter: A Novel Approach to Enabling Heparin-Free Frequent Daily Home Hemodialysis.

Authors:  Adam Locke; Margaret A Bushey; Cynthia LaCroix; Patience Deardoff; Macaulay Amechi Chukwukadibia Onuigbo
Journal:  Mayo Clin Proc Innov Qual Outcomes       Date:  2020-11-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.